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What’s New:  
 
Previous tumor transplantation studies in mice showed that endogenous T cells can 
prevent tumor recurrence after oncogene-inactivation therapy. But, these 
experiments neglected the long-term, usually tolerogenic, interaction of de novo 
malignancies with the immune system. Here, we found that during autochthonous 
tumor regression surviving tumor cells were not eradicated by endogenous T cells 
and regrew after therapy cessation. However, adoptively transferred T cell targeting 
the cancer-driving oncogene eradicated relapsed tumors showing a successful 




Targeted oncogene inactivation by small molecule inhibitors can be very effective but tumor 
recurrence is a frequent problem in the clinic. Therapy by inactivation of the cancer-driving 
oncogene in transplanted tumors was shown to be augmented in the presence of T cells. 
However, these experiments did not take into account the long-term, usually tolerogenic, 
interaction of de novo malignancies with the immune system. Here, we employed mice, in 
which SV40 large T (Tag) and firefly luciferase (Luc) as fusion protein (TagLuc) could be 
regulated with the Tet-on system and upon activation resulted in tumors after a long latency. 
TagLuc inactivation induced profound tumor regression, demonstrating sustained oncogene 
addiction. While tumor relapse after TagLuc inactivation was prevented in immunocompetent 
mice bearing transplanted tumors, autochthonous tumors relapsed or recurred after therapy 
discontinuation indicating that the immune system that coevolved with the malignancy over 
an extended period of time lost the potency to mount an efficient anti-tumor immune 
response. By contrast, adoptively transferred CD8+ T cells targeting the cancer-driving 
oncogene eradicated recurrent autochthonous tumors, highlighting a suitable therapy option 
in a clinically relevant model.  
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Introduction 
Small molecule inhibitors, designed to inactivate specifically a cancer-driving oncogene have 
been proven to be highly effective against a variety of cancers in the clinic, e.g. imatinib 
against BCR-ABL-driven leukemia [1]. Despite the revolutionary success of small molecule 
inhibitors, drug resistance and, hence, tumor recurrence, is a frequently observed problem in 
the clinic. Various preclinical animal models revealed that abrogation of the cancer-driving 
oncogene provokes tumor cell apoptosis, necrosis, senescence, autophagy, and/or 
differentiation, collectively proving oncogene addiction [2-9]. These cell autonomous 
mechanisms were long thought to be the primary mechanism responsible for tumor 
regression. However, recently, it was discovered in a c-myc-driven tumor transplantation 
model that CD4+ T cells contribute to sustained tumor regression upon oncogene inactivation 
by release of chemokines like thrombospondins that remodel the tumor microenvironment, 
showing that cell extrinsic mechanism, namely cells of the adaptive immune system, 
contribute to the therapeutic effect of oncogene inactivation [10].  
The finding that cancer cell-targeting drugs are not solely tumor cell autonomous but involve 
T cells was already described for cancer cells equipped with suicide genes that conferred cell 
death in vivo after application of the corresponding prodrug. T cell-competent mice rejected 
transplanted cancer cells following prodrug treatment, while tumors relapsed in T cell-
deficient mice [11]. Later, it was found that cancer cell death was immunogenic when 
induced by certain chemotherapeutic drugs, e.g. anthracyclines, and that so treated cancer 
cells induced T cell-dependent tumor immunity in transplantation models [12, 13]. We 
showed in a model of large established transplanted tumors that therapeutic efficacy of 
oncogene inactivation was increased when immunodeficient hosts were reconstituted with T 
cells [5]. 
So far, the therapeutic effect of drug-driven anticancer therapies and the contribution of the 
immune system were mainly analyzed in experimental models with transplanted tumors. 
These models do not recapitulate the clinical situation because transplanted tumors, 
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although histologically not to discriminate from autochthonous tumors [14], grow in a short 
time to large tumors so that the interaction between cancer and immune cells is limited to few 
weeks. Mouse transplantation models do therefore not recapitulate the long-lasting interplay 
between cancer and the immune system as it occurs during autochthonous tumor 
development, which is usually sporadic, clonal and may last for decades in humans. 
Importantly, the process of cancer cell inoculation is associated with an acute inflammatory 
response facilitating T cell activation as it unlikely occurs during autochthonous tumor 
development. It remains therefore questionable if the results obtained from mice transplanted 
with cancer cells are predictive for cancer patients presenting in the clinic. Here, we 
established a model in which autochthonous tumors can be induced and treated by 
oncogene inactivating drugs. With this model we wanted to answer the question whether the 
immune system eradicates drug resistant cancer clones during oncogene inactivation 
therapy and prevents cancer recurrence after therapy discontinuation.  
Material and Methods 
Mice  
Rag-1-/- or Rag-2-/- (Rag-/-) mice and TCR-I mice, which are transgenic for the H2-Db-restricted 
Tag epitope I-specific (Vβ7) T cell receptor [15], were obtained from The Jackson Laboratory. 
LoxP-TagLuc-pA mice [16], TREloxPstoploxPTagLuc mice [5], CAG-rtTA mice expressing the 
reverse transactivator rtTA2S-M2 [17], TCR-I x ChRLuc mice [18], all generated on a C57Bl/6 
genetic background, and Tyr::Cre mice [19], were described elsewhere. Homozygous 
TREloxPstoploxPTagLuc mice were crossed to Tyr::Cre+/-/CAG-rtTA+/- mice to obtain TTC mice 
that were heterozygous for all three transgenes. To obtain mice with albino phenotype, mice 
were bred to C57BL/6-Tyrc-Brd mice [20]. All animal experiments were conducted in 
accordance with institutional and national guidelines and regulations, after approval by the 
Landesamt für Gesundheit und Soziales (Berlin). 
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Cancer Cell Lines 
Cells were cultured in Dulbecco’s modified eagle medium (GIBCO), supplemented with 10% 
heat-inactivated fetal calf serum (PAN, Biotech) and 50 µg/ml gentamicin (GIBCO). For in 
vitro analyzes, cancer cell lines from primary tumors grown in TTC triple transgenic mice 
were established by collagenase digestion (type II, 1mg/ml, Invitrogen) of small tumor 
fragments. Obtained cell lines were cultured in the presence of dox (1 µg/ml). Additionally, 
the mouse melanoma cell line B16 was used to detect tyrosinase transcripts by RT-PCR. For 
tumor challenge experiments, 1x106 Tet-TagLuc tumor cells or 50 to 100 µl fragments (about 
1 x 1 x 1 mm cubes) derived from Tet-TagLuc tumors grown in Rag-/- mice were injected 
subcutaneously into indicated mice. Tumor growth and regression, respectively, were 
analyzed by BL imaging and determination of tumor volume by caliper measurement 
according to the formula (xyz)/2. 
Doxycycline Treatment 
Dox (0.2 mg/ml; Sigma) was administered by light-protected drinking water supplemented 
with 5% sucrose changed twice a week, or 1 µg/ml dox was added to the cell culture medium 
twice a week. 
Bioluminescent Detection 
Mice were anesthetized by isofluran inhalation using the XGI-8 Gas Anesthesia System 
(Xenogen) and received 3 mg of D-luciferin (Biosynth) intravenously dissolved in PBS (30 
mg/ml) to detect TagLuc (firefly luciferase) tumor signal or received intravenously 100 µg 
coelenterazine (Biosynth), dissolved in 30% DMSO (Sigma-Aldrich) and 70% PBS (MgCl2 
and CaCl2 free (Invitrogen)) to detect RLuc T cell signal. Mice were directly subjected to BL 
imaging (IVIS 200, Xenogen). The exposure time for BL image acquisition was 1 or 60 
second, depending on the signal strength. The BL imaging data were analyzed with Living 
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Image software (Caliper Life Science). BL signal was quantified by placing a region of 
interest (ROI) around individual tumors. 
Adoptive T Cell Transfer 
Spleen cells of TCR-I x ChRLuc mice were isolated seven days after immunization with 1x107 
Tag+ 16.113 cells [21] and spleen cells containing 5 x 106 Vb7+ cells were injected 
intravenously into mice that were irradiated with 4 or 5 grey on the same day.  
Flow cytometry and antibodies 
TCR-I x ChRLuc transgenic spleen cells were stained with following anti-mouse antibodies 
before transfer at a final concentration of 1:100: CD3 (145-2C11, Phycoerythrin (PE), 
BioLegend), CD8 (53-6.7, allophycocyanin (APC), BioLegend), and Vb7 (TR310, fluorescein 
isothiocyanate (FITC), BioLegend). Blood samples were stained with H2-Db tetramers 
loaded with peptide I (SAINNYAQKL) (PE, MBL), CD8 (53-6.7, APC, BioLegend) and CD3 
(17-A2, FITC). Erythrocytes from blood samples and spleen cells were lysed by BD™ Lysing 
solution (BD) and ammonium chloride treatment, respectively. Samples were washed in PBS 
and acquired using FACSCalibur (BD). Data analysis was performed using FlowJo software 
(TreeStar, Ashland, OR, USA) 
Histology 
H&E staining of sections from paraffin embedded tumors were performed according to 
standard techniques. Pathological analyses were performed by ECVP certified veterinary 
pathologists (OK, ADG). 
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PCR 
To determine recombination status of tumors developed in TTC mice, the following primer 
pairs were used: #1 forward primer: 5’-CGAGGTAGGCGTGTACGGTGG-3’, #1 reverse 
primer: 5’-GCAAATTTAAAGCGCTGATGATCC-3’, 
#2 forward primer: 5’-CGAGGTAGGCGTGTACGGTGG-3’, #2 reverse primer: 5’-
CGGATGAGCATTCATCAGGCGGG-3’. 
RT-PCR 
RNA was isolated using the RNA isolation kit from Stratec. After DNase treatment, cDNA 
was reverse transcribed using SuperScriptIII reverse transcriptase and oligo (dT) primer (life 
technology). To detect tyrosinase transcripts, the following primers (exon spanning) were 
used: forward primer: 5’-TGTACAGAGAAGCGAGTCTTGA-3’; reverse primer: 5’-
ACAAATGATCTGCCAGGAGGA-3’. Beta actin cDNA was amplified using following primer 
pair: forward primer: 5’-ACCACACCTTCTA-CAATGAG-3’, reverse primer: 5’-
GTAGATGGGCA-CAGTGTGGG-3’. 
Results 
Prevention of transplanted tumor relapse after oncogene inactivation in 
immunocompetent mice 
Tet-TagLuc is a fibrosarcoma cell line derived from a TREloxPstoploxPTagLuc transgenic 
mouse (see below) and has been described (5). Tet-TagLuc cells express a fusion protein of 
SV40 large T (Tag) and firefly luciferase (TagLuc) as cancer-driver under tetracycline 
promoter control, which can be regulated by doxycycline (dox). Previously, we observed that 
the frequency of tumor relapse after oncogene inactivation therapy could be reduced in the 
presence of an intact immune system. [5]. To extend the data, we exploited LoxP-TagLuc-pA 
[16] x CAG-rtTA [17] double transgenic mice to enable growth of Tet-TagLuc cells, a 
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regressor cancer cell line in wildtype mice. Although LoxP-TagLuc-pA x CAG-rtTA mice are 
tolerant for TagLuc and transactivator antigens, Tet-TagLuc cells injected subcutaneously as 
single cell suspension were rapidly rejected (Figure 1A), indicating the presence of at least 
one additional transplantation rejection antigen. Transplantation of Tet-TagLuc tumor 
fragments into LoxP-TagLuc-pA x CAG-rtTA mice prevented tumor rejection and tumors 
grew progressively in all mice. After an average tumor growth period of 28 days (range 22 to 
34 days), tumors reached a size of at least 500 mm3 and TagLuc inactivation by dox 
application was started (Figure 1B and C). TagLuc inactivation resulted in rapid decline of 
bioluminescence (BL) signal and tumors regressed as followed by BL imaging and caliper 
measurement, respectively (Figure 1B and C). Tumors of all Rag-/- mice initially regressed 
but then relapsed around 1 month after therapy. In contrast, tumors from 6 out of 7 
immunocompetent LoxP-TagLuc-pA x CAG-rtTA mice did not relapse, although, a small, soft 
lump at the tumor side remained but did not progress. These results suggested that 
therapeutic efficacy of oncogene-inactivation therapy depends on the presence of an intact 
adaptive immune system in a tumor transplantation model, similar as has been reported by 
Rakhra et al. [10]. Furthermore, tumors in LoxP-TagLuc-pA x CAG-rtTA mice, although 
grown for more than one month in the presence of the adaptive immune system, seemed not 
to have induced tolerance of endogenous tumor-reactive T cells. 
TTC mice develop autochthonous tumors  
The previous experiment utilized transplantation of cancer cells under the skin that progress 
in a relatively short period to full-blown tumors. To analyze whether our observations can be 
extended to tumors initiated and evolved in a primary host with a much longer coevolution 
between cancer and T cells, we utilized TREloxPstoploxPTagLuc transgenic mouse lines 
described previously [5]. Like Tet-TagLuc cells, TREloxPstoploxPTagLuc transgenic mice 
contain the TagLuc fusion gene under control of the Tet-promoter, but due to a loxP-flanked 
stop cassette located between the Tet-promoter and the TagLuc transgene, and the 
requirement of an active transactivator, expression was prevented in TREloxPstoploxPTagLuc 
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single transgenic mice (Figure 2A). We aimed to achieve TagLuc expression under control of 
the Tet-on system in a melanocyte-restricted fashion to establish an autochthonous 
melanoma model. To this end, we crossed TREloxPstoploxPTagLuc mice derived from two 
founder lines (F7 and F10) to CAG-rtTA and Tyr::Cre [19]transgenic mice, which express the 
rtTA and Cre transgenes under the CAG and tyrosinase promoter, respectively (Figure 2A). 
TagLuc expression was not detectable by BL imaging in the absence of dox in 
TREloxPstoploxPTagLuc single (T), TREloxPstoploxPTagLuc x CAG-rtTA double (TC), and 
TREloxPstoploxPTagLuc x CAG-rtTA x Tyr::Cre triple transgenic (TTC) mice of both founder 
lines, as shown for F7 in Figure 2B. Dox administration via the drinking water (200 µg/ml) 
resulted in profound induction of TagLuc expression in TTC triple transgenic mice (Figure 2B 
and C). Low TagLuc expression was detected in TC double transgenic mice (mean average 
radiance TC F7 vs TTC F7, 5.17E+03 ± 1.48E+03 vs 3.79E+04 ± 3.62E+04; TC F10 vs TTC 
F10, 3.91E+03 ± 6.3E+02 vs 6.56E+05 ± 1.74E+06), most likely due to weak leakiness of the 
stop cassette. No tumor formation was observed in TC double transgenic mice with one 
exception for each founder line (F7: 1 out of 16 observed mice; F10: 1 out of 13 observed 
mice; average observation period: 42 and 36 weeks, respectively) (data not shown). TTC 
triple transgenic mice treated with dox since birth developed primarily non-pigmented skin 
tumors and visceral tumors (Figure 2D) with an average tumor latency of 42 weeks (F7) and 
35 weeks (F10), respectively (Figure 2E). Histological analysis of 14 tumors isolated from 
eleven TTC mice revealed that the majority of tumors (8/14) were spindle cell tumors, but 
also pancreatic exocrine adenocarcinomas (n=2), mammary adenocarcinomas (n=2), 
papilloma (n=1) and a round cell tumor were identified (Figure 2F and Table 1). In all 
analyzed tumors, deletion of the stop cassette was detected (Figure 2G), however, none of 
the isolated tumors showed tyrosinase promoter activity as analyzed by detection of 
tyrosinase expression (Figure 2H). These results suggest that tumors arose from progenitor 
cells that deleted the stop cassette due to transient tyrosinase promoter activity but these 
cells did not commit to the melanocyte lineage. We assume that cells from these progenitor 
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cells transformed with higher penetrance than melanocytes so that mice succumbed to non-
melanoma tumors before melanomas could develop. 
Autochthonous tumors regress long-term following oncogene inactivation but 
dormant tumor cells regrow after therapy discontinuation 
Tumor-bearing TTC mice with one (n=6), two (n=3) or more tumors (n=1) were subjected to 
oncogene inactivation therapy by withdrawal of dox-containing drinking water. The average 
age of mice at the time point of treatment was 298 days (range 166 to 584 days) (Table 2). 
Dox cessation resulted in a rapid decrease of BL signal in all treated mice (n=10), declining 
to less than 2% (range 0.009 to 10.5 %) of the original signal strength after an average 
observation period of eight days as shown for seven mice (Figure 3A and B and Figure S1). 
Decline of BL signal was followed by tumor regression, suggesting abundant cell death 
(Figure 3C). From in vitro analysis of cancer cell lines derived from the transgenic mice we 
know that TagLuc inactivation results in apoptotic cell death in a high proportion of cells (up 
to more than 50%) (unpublished observation). To analyze whether TagLuc inactivation in 
autochthonous tumor-bearing mice resulted in complete tumor cell eradication, eight of the 
ten mice with stably low BL signal over time (average observation period 83 days; range 19 
to 203 days) were subjected again to dox-containing drinking water. Surprisingly, BL signal 
increased rapidly in all mice after dox reapplication and tumors developed at the primary 
tumor site as shown for six mice in Figure 3D-F and Figure S1. Together, oncogene 
inactivation in autochthonous tumor-bearing hosts resulted in relatively durable tumor 
regression, but, more importantly, in all treated mice some tumor cells survived and 
remained dormant for several weeks and up to six months, able to resume proliferation as 
soon as TagLuc was reactivated. These results suggest that massive tumor cell death 
induced by oncogene inactivation does not elicit an immune response potent enough to 
prevent tumor progression upon oncogene reexpression.  
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Adoptively transferred TE cells eradicate autochthonous tumors that relapsed after 
oncogene inactivation  
To analyze antigenicity of dormant cancer cells that persisted after oncogene inactivation in 
the autochthonous host, two tumor-bearing TTC transgenic mice were subjected to TagLuc 
inactivation therapy (Figure 4A). A relatively low but stable Tag-Luc signal at the former 
tumor site was detectable more than one month after TagLuc inactivation indicating the 
presence of dormant tumor cells. These mice were irradiated (5 grey) and received 
monospecific CD8+ T cells (5x106 cells) directed against Tag epitope I (TE cells) isolated from 
immunized TCR-I x ChRLuc double transgenic mice. Expansion and migration of transferred 
T cells were followed by detection of Renilla luciferase (RLuc, which can be distinguished 
from firefly luciferase in TagLuc) T cell signal by BL imaging over time (Figure 4A). Two days 
after TE cell transfer, an RLuc T cell signal was localized predominantly in cervical lymph 
nodes and between day 5-16 also at the previous tumor site indicating that dormant tumor 
cells were antigenic and recognized by TE cells in the primary host.  
Regularly, we observed mice with reappearing BL signal despite continuous oncogene 
inactivation therapy indicating tumor relapse due to drug resistance. To ask whether 
transferred TE cells could eradicate autochthonous tumors that escaped oncogene 
inactivation therapy, we irradiated nine mice with drug resistant tumors and injected 5x106 TE 
cells. Tumor rejection by transferred TE cells was monitored by detection of TagLuc tumor 
signal over time. A reduction in TagLuc activity at the tumor site was observed starting at day 
four after TE cell transfer and no tumor TagLuc signal was detectable after 12 days in all mice 
(Figure 4B and C and Figure S2). Irradiation alone did not result in tumor eradication (n=1, 
data not shown). Tumor rejection was accompanied by robust TE cells expansion, reaching 
TE cell counts of up to 89 % of the total T cell population at day ten after transfer (average 
46.2 %) as shown in Figure 4D (n=5). While one mouse died seven days after TE cell transfer 
and decline of TagLuc tumor signal, the remaining eight mice were observed long-term (54 to 
180 days) and tumors did not relapse (Figure S2). Together, dormant tumor cells are 
antigenic and recognized by transferred TE cells. Furthermore, TE cell therapy proved to be 
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effective to eradicate tumor variants that escaped destruction by oncogene inactivating 
therapy in primary tumor-bearing hosts. In conclusion, immunogenic cell death after 
oncogene inactivation therapy, if at all operative, could neither prevent eventual tumor 
relapse nor tumor progression after therapy discontinuation in autochthonous tumor bearing 
hosts. 
Discussion 
In the present study, we analyzed the role of the host immune system for sustained tumor 
regression after oncogene inactivation therapy. In mice with transplanted tumors we found a 
substantial improvement of the therapeutic outcome of oncogene inactivation therapy 
dependent on the presence of an intact immune system, confirming earlier studies (5, 10). 
Since the mice were tolerant for TagLuc and rtTA and Tet-TagLuc cancer cells were rejected 
as single cell suspension but grew as fragments [22], we can postulate additional, yet 
unknown, tumor transplantation rejection antigen(s). These data strongly indicate that cancer 
cell death induced by oncogene inactivation can be immunogenic under special conditions 
(the artificial process of cancer cell injection causing acute inflammation) and elicits T cells 
that reject transplanted cancer cells. However, when the same therapeutic approach was 
analyzed against autochthonous tumors, tumors frequently relapsed under therapy or 
recurred after therapy discontinuation. This contrasting effect might be due to the different 
time period the immune system interacted with the tumor and its microenvironment in the 
transplanted versus the autochthonous tumor model. The period was relatively short in mice 
with transplanted tumors but long during autochthonous tumor development. An extended 
period of time in which T cells encounter their cognate antigen can result in T cell exhaustion 
that might have hampered the contribution of T cells to the therapeutic effect of oncogene 
inactivation in mice with autochthonous tumors. This assumption is supported by clinical data 
and an autochthonous cancer model, demonstrating therapeutic effects by so-called 
checkpoint inhibitors like anti-PD-1 (ligand) antibodies that unleash tumor-reactive T cells 
from suppression [24-26]. In addition, the inflammation created by tumor cell injection in the 
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transplanted tumor model might have increased the number of pre-existing tumor infiltrating 
T cells facilitating anti-cancer activity after oncogene inactivation in an artificial manner. 
Like for other oncogenes including ras, myc, bcr-abl [2, 4, 27], the growth and survival of 
cancer cells in the current model remained long-term dependent on the expression of 
TagLuc. These data are at variance with previous data suggesting that tumors at advanced 
stage progress independent of Tag expression [28]. However, in this model a version of the 
transactivator was used that did not allow as tight regulation as rtTA used here. Also in 
common with other oncogenes, TagLuc inactivation resulted in complete regression of large 
tumors, yet some cancer cells escaped elimination in a dormant state and could rapidly be 
reactivated upon drug discontinuation [2, 8, 29] or became drug-resistant, e.g. through 
mutations in the rtTA conferring dox-unresponsiveness [5, 30]. Identifying cancer specific 
point mutations in tumor samples taken prior oncogene inactivation and engineering T cells 
with receptors that target these mutations might be a promising approach to combat 
relapsing tumors after oncogene inactivation therapy in the clinic. In conclusion, in a clinically 
relevant model, adoptive T cell therapy but not therapy targeting a cancer-driving oncogene 
can prevent autochthonous tumor recurrence occurring spontaneously or upon treatment 
discontinuation. 
Acknowledgement 
The authors thank I. Becker and M. Babka for excellent technical assistance and I. Hoeft and 
M. Roesch for animal care service. This work was supported by the Deutsche 





1 Jabbour, E., Cortes, J. and Kantarjian, H., Long-term outcomes in the 
second-line treatment of chronic myeloid leukemia: a review of tyrosine kinase 
inhibitors. Cancer 2011. 117: 897-906. 
2 Chin, L., Tam, A., Pomerantz, J., Wong, M., Holash, J., Bardeesy, N., 
Shen, Q., O'Hagan, R., Pantginis, J., Zhou, H., Horner, J. W., 2nd, Cordon-
Cardo, C., Yancopoulos, G. D. and DePinho, R. A., Essential role for 
oncogenic Ras in tumour maintenance. Nature 1999. 400: 468-472. 
3 Wu, C. H., van Riggelen, J., Yetil, A., Fan, A. C., Bachireddy, P. and 
Felsher, D. W., Cellular senescence is an important mechanism of tumor 
regression upon c-Myc inactivation. Proc Natl Acad Sci U S A 2007. 104: 
13028-13033. 
4 Felsher, D. W. and Bishop, J. M., Reversible tumorigenesis by MYC in 
hematopoietic lineages. Mol Cell 1999. 4: 199-207. 
5 Anders, K., Buschow, C., Herrmann, A., Milojkovic, A., Loddenkemper, 
C., Kammertoens, T., Daniel, P., Yu, H., Charo, J. and Blankenstein, T., 
Oncogene-targeting T cells reject large tumors while oncogene inactivation 
selects escape variants in mouse models of cancer. Cancer Cell 2011. 20: 
755-767. 
6 Felsher, D. W., Tumor dormancy and oncogene addiction. APMIS 2008. 116: 
629-637. 
7 Moody, S. E., Sarkisian, C. J., Hahn, K. T., Gunther, E. J., Pickup, S., 
Dugan, K. D., Innocent, N., Cardiff, R. D., Schnall, M. D. and Chodosh, L. 
A., Conditional activation of Neu in the mammary epithelium of transgenic 
mice results in reversible pulmonary metastasis. Cancer Cell 2002. 2: 451-
461. 
8 Shachaf, C. M., Kopelman, A. M., Arvanitis, C., Karlsson, A., Beer, S., 
Mandl, S., Bachmann, M. H., Borowsky, A. D., Ruebner, B., Cardiff, R. D., 
Yang, Q., Bishop, J. M., Contag, C. H. and Felsher, D. W., MYC inactivation 
uncovers pluripotent differentiation and tumour dormancy in hepatocellular 
cancer. Nature 2004. 431: 1112-1117. 
9 Anders, K. and Blankenstein, T., Molecular pathways: comparing the effects 
of drugs and T cells to effectively target oncogenes. Clin Cancer Res 2013. 
19: 320-326. 
10 Rakhra, K., Bachireddy, P., Zabuawala, T., Zeiser, R., Xu, L., Kopelman, 
A., Fan, A. C., Yang, Q., Braunstein, L., Crosby, E., Ryeom, S. and 
Felsher, D. W., CD4(+) T cells contribute to the remodeling of the 
microenvironment required for sustained tumor regression upon oncogene 
inactivation. Cancer Cell 2010. 18: 485-498. 
11 Uckert, W., Kammertons, T., Haack, K., Qin, Z., Gebert, J., Schendel, D. J. 
and Blankenstein, T., Double suicide gene (cytosine deaminase and herpes 
simplex virus thymidine kinase) but not single gene transfer allows reliable 
elimination of tumor cells in vivo. Hum Gene Ther 1998. 9: 855-865. 
12 Casares, N., Pequignot, M. O., Tesniere, A., Ghiringhelli, F., Roux, S., 
Chaput, N., Schmitt, E., Hamai, A., Hervas-Stubbs, S., Obeid, M., Coutant, 
F., Metivier, D., Pichard, E., Aucouturier, P., Pierron, G., Garrido, C., 
 16 
Zitvogel, L. and Kroemer, G., Caspase-dependent immunogenicity of 
doxorubicin-induced tumor cell death. J Exp Med 2005. 202: 1691-1701. 
13 Obeid, M., Tesniere, A., Ghiringhelli, F., Fimia, G. M., Apetoh, L., 
Perfettini, J. L., Castedo, M., Mignot, G., Panaretakis, T., Casares, N., 
Metivier, D., Larochette, N., van Endert, P., Ciccosanti, F., Piacentini, M., 
Zitvogel, L. and Kroemer, G., Calreticulin exposure dictates the 
immunogenicity of cancer cell death. Nat Med 2007. 13: 54-61. 
14 Schreiber, K., Rowley, D. A., Riethmuller, G. and Schreiber, H., Cancer 
immunotherapy and preclinical studies: why we are not wasting our time with 
animal experiments. Hematol Oncol Clin North Am 2006. 20: 567-584. 
15 Staveley-O'Carroll, K., Schell, T. D., Jimenez, M., Mylin, L. M., Tevethia, 
M. J., Schoenberger, S. P. and Tevethia, S. S., In vivo ligation of CD40 
enhances priming against the endogenous tumor antigen and promotes CD8+ 
T cell effector function in SV40 T antigen transgenic mice. J Immunol 2003. 
171: 697-707. 
16 Buschow, C., Charo, J., Anders, K., Loddenkemper, C., Jukica, A., 
Alsamah, W., Perez, C., Willimsky, G. and Blankenstein, T., In vivo imaging 
of an inducible oncogenic tumor antigen visualizes tumor progression and 
predicts CTL tolerance. J Immunol 2010. 184: 2930-2938. 
17 Anders, K., Buschow, C., Charo, J. and Blankenstein, T., Depot formation 
of doxycycline impairs Tet-regulated gene expression in vivo. Transgenic Res 
2012. 21: 1099-1107. 
18 Charo, J., Perez, C., Buschow, C., Jukica, A., Czeh, M. and Blankenstein, 
T., Visualizing the dynamic of adoptively transferred T cells during the 
rejection of large established tumors. Eur J Immunol 2011. 41: 3187-3197. 
19 Delmas, V., Martinozzi, S., Bourgeois, Y., Holzenberger, M. and Larue, L., 
Cre-mediated recombination in the skin melanocyte lineage. Genesis 2003. 
36: 73-80. 
20 Zheng, B., Vogel, H., Donehower, L. A. and Bradley, A., Visual genotyping 
of a coat color tagged p53 mutant mouse line. Cancer Biol Ther 2002. 1: 433-
435. 
21 Willimsky, G. and Blankenstein, T., Sporadic immunogenic tumours avoid 
destruction by inducing T-cell tolerance. Nature 2005. 437: 141-146. 
22 Singh, S., Ross, S. R., Acena, M., Rowley, D. A. and Schreiber, H., Stroma 
is critical for preventing or permitting immunological destruction of antigenic 
cancer cells. J Exp Med 1992. 175: 139-146. 
23 Schietinger, A., Philip, M., Krisnawan, V. E., Chiu, E. Y., Delrow, J. J., 
Basom, R. S., Lauer, P., Brockstedt, D. G., Knoblaugh, S. E., Hammerling, 
G. J., Schell, T. D., Garbi, N. and Greenberg, P. D., Tumor-Specific T Cell 
Dysfunction Is a Dynamic Antigen-Driven Differentiation Program Initiated 
Early during Tumorigenesis. Immunity 2016. 45: 389-401. 
24 Willimsky, G., Schmidt, K., Loddenkemper, C., Gellermann, J. and 
Blankenstein, T., Virus-induced hepatocellular carcinomas cause antigen-
specific local tolerance. J Clin Invest 2013. 123: 1032-1043. 
25 Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., 
Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., 
Akerley, W., van den Eertwegh, A. J., Lutzky, J., Lorigan, P., Vaubel, J. 
M., Linette, G. P., Hogg, D., Ottensmeier, C. H., Lebbe, C., Peschel, C., 
Quirt, I., Clark, J. I., Wolchok, J. D., Weber, J. S., Tian, J., Yellin, M. J., 
Nichol, G. M., Hoos, A. and Urba, W. J., Improved survival with ipilimumab in 
patients with metastatic melanoma. N Engl J Med 2010. 363: 711-723. 
 17 
26 Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., 
McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, 
M. B., Leming, P. D., Spigel, D. R., Antonia, S. J., Horn, L., Drake, C. G., 
Pardoll, D. M., Chen, L., Sharfman, W. H., Anders, R. A., Taube, J. M., 
McMiller, T. L., Xu, H., Korman, A. J., Jure-Kunkel, M., Agrawal, S., 
McDonald, D., Kollia, G. D., Gupta, A., Wigginton, J. M. and Sznol, M., 
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl 
J Med 2012. 366: 2443-2454. 
27 Huettner, C. S., Zhang, P., Van Etten, R. A. and Tenen, D. G., Reversibility 
of acute B-cell leukaemia induced by BCR-ABL1. Nat Genet 2000. 24: 57-60. 
28 Ewald, D., Li, M., Efrat, S., Auer, G., Wall, R. J., Furth, P. A. and 
Hennighausen, L., Time-sensitive reversal of hyperplasia in transgenic mice 
expressing SV40 T antigen. Science 1996. 273: 1384-1386. 
29 Boxer, R. B., Jang, J. W., Sintasath, L. and Chodosh, L. A., Lack of 
sustained regression of c-MYC-induced mammary adenocarcinomas following 
brief or prolonged MYC inactivation. Cancer Cell 2004. 6: 577-586. 
30 Podsypanina, K., Politi, K., Beverly, L. J. and Varmus, H. E., Oncogene 
cooperation in tumor maintenance and tumor recurrence in mouse mammary 





Figure 1.  Sustained regression of transplanted tumors after oncogene inactivation 
therapy in immunocompetent hosts. (A) LoxP-TagLuc-pA x CAG-rtTA mice (n=5) were 
injected with Tet-TagLuc cancer cells and BL signal was followed over time. Data represent a 
single experiment. (B) LoxP-TagLuc-pA x CAG-rtTA mice (n=7) or Rag-/- mice (n=6) were 
injected with Tet-TagLuc tumor fragments, and, when tumor reached a size of >500 mm3, 
mice were treated with dox or were left untreated (n=1). FLuc tumor signal was followed over 
time by BL imaging. (C) Tumor growth kinetics of mice shown in (B). Data in (B) and (C) are 
combined from three experiments. 
Figure 2.  Autochthonous tumor model allowing oncogene-inactivation therapy. (A) 
Scheme of the breeding strategy to generate mice that conditionally express TagLuc fusion 
protein in the presence of dox. (B) Mice transgenic for TREloxPstoploxPTagLuc (T) (n=5), 
TREloxPstoploxPTagLuc and CAG-rTA (TC) (n=7), or TREloxPstoploxPTagLuc, CAG-rtTA and 
Tyr::Cre (TTC) (n=16) were subjected to BL imaging before and after induction by dox 
(acquisition time 60 seconds). One representative example for each genotype is shown. (C) 
Average light signal of TC and TTC mice of founder line 7 and 10 before (white circle) and 
after induction (black triangle) by dox. Light signals of B6 mice denote background. Each 
symbol indicates an individual mouse. Mice with albino phenotype are indicated with hatched 
symbols in the “after dox” situation. (D) Photographs of seven tumor bearing TTC mice. In 
one mouse (top left), the abdominal wall was opened to reveal the visceral tumor (white 
arrow) that shows firefly luciferase activity (adjacent picture). (E) Tumor-free survival of TTC 
mice of founder line 7 and 10 after dox administration. Mice were counted as tumor bearing 
when a locally increasing signal was detectable by BL imaging with an exposure time of one 
second. Crosses indicate mice that were censored. (F) Light microscopy of H&E stained 
sections from tumors located at the snout (left) or pancreas (right). Scale bar 50 µm. (G) 
Tumors of TTC mice were analyzed for deletion of the loxP site-flanked stop cassette using 
two different primer pairs (#1 and #2). Primer location and expected band size are indicated. 
Two representative results (tumor #6653 and #5276) are shown. Exemplary PCR results of a 
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tumor with (Tet-TagLuc) and without recombination (TC 200.09) of the stop cassette are 
shown. (H) RT-PCR to analyze tyrosinase expression in cell lines (n=5) derived from tumors 
grown in TTC mice. Melanoma tumor cell line B16 served as positive control. Beta actin was 
detected as internal control. 
Figure 3.  Autochthonous tumor regression following oncogene inactivation and 
regrowth of dormant cells after therapy discontinuation. (A) Primary tumor-bearing TTC 
mice (n=10) receiving dox for an average period of 298 days (range from 166 to 584) were 
subjected to oncogene inactivation therapy (dox off). TagLuc expression was followed by BL 
imaging over time (one second acquisition time). (B) Quantified BL signal from mice shown in 
(A). (C) Photograph of a tumor-bearing TTC mouse shown in the lower panel in (A) before 
and 27 days after dox cessation. The same mouse is also shown in Figure 2D. (D) A TTC 
mouse with two primary tumors was monitored over time by BL imaging after dox cessation 
and reapplication 203 days later. (E) Quantified BL signal over time of tumor located at the 
snout (white filled circle) and abdominal cavity (black filled circle) from mouse shown in (D). 
A red filled circle indicates time point of dox reapplication. (F) Photographs of the snout 
tumor from mouse shown in (D and E) before and after dox reapplication. See also related 
supplementary Figure S1 and Table 2. 
 
Figure 4.  Adoptively transferred TE cells recognize dormant tumor cells and 
eradicate tumors that relapsed during target drug therapy. (A) Primary tumor-
bearing TTC mice (n=2) were subjected to oncogene inactivation therapy and tumor 
regression was monitored by detection of tumor TagLuc signal before and after dox 
cessation (left panel). Mice were irradiated, injected with 5x106 RLuc+ TCR-I TE cells 
and RLuc T cell signal was monitored over time by BL imaging (right panel). (B) 
Primary tumor-bearing TTC mice were treated by dox cessation and tumor 
regression was followed by BL imaging. When BL signal was increasing despite 
continued dox cessation that indicated tumor relapse, mice (n=9) were irradiated and 
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received a single injection of TE cells. Kinetic of tumor eradication by T cells was 
monitored by BL imaging of tumor TagLuc activity. (C) Quantified TagLuc signal of 
mice shown in (B). Time point of dox cessation and T cell therapy are indicated by 
blue circle and black arrow, respectively. Two representative examples from nine 
treated mice are shown in (B) and (C). (D) Percentage of TE cells in blood of 
immunized C57BL/6 (n=2) or tumor bearing TTC mice (n=5), respectively, ten days 
after T cell therapy. One representative dot blot is shown (left) and all data are 
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Figure	 S1.	 (A)	 TTC	 mice	 were	 subjected	 to	 oncogene	 inac;va;on	 therapy	 by	 dox	
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Figure S2. Autochthonous tumor development in TTC mice was monitored by BL imaging. 
Mice with tumors received oncogene inactivation therapy (blue circle). After recurrence of 
light signal despite continuous dox cessation, mice were irradiated and received TE cells 
(red circle). Seven individual mice are shown. Mice #10539 and #9774 received dox-





Table 1: Tumors developed in TREloxPstoploxPTagLuc /CAG-rtTA/Tyr::Cre (TTC) 
transgenic mice  







1 TTC #7496 Rectum M ++ + Spindle cell tumor
A) 
2 TTC #7679a Abdomen E +++ - 
Mammary 
adenocarcinoma 
3 TTC #7679b Subcutanous E +++ - 
Mammary 
adenocarcinoma 
4 TTC #6653 Abdomen E +++ + 
Pancreatic exocrine 
adenocarcinoma 
5 TTC #3055a Snout M ++ + Spindle cell tumor
A) 
6 TTC #3055b Abdomen E + + 
Pancreatic exocrine 
adenocarcinoma 
7 TTC #3059 Armpit M ++ + Spindle cell tumor
A) 
8 TTC #5785 Abdomen M +++ + Spindle cell tumor
A) 
9 TTC #6354a Snout M ++ + Spindle cell tumor
A) 
10 TTC #6354b Ear E - - Papilloma 
11 TTC #5276 Ear M ++ + Spindle cell tumor
A) 




cell + +/- 
Desmoplastic small-
round cell tumor 
13 TTC #5650 Rectum E +++ + Spindle cell tumor
A) 
14 TTC #6654 Limb E +++ + Spindle cell tumor
A) 
A) Most likely differentials: Peripheral nerve sheath tumor, leiomyosarcoma or fibrosarcoma 
M = mesenchymal morphology 
E = epithelial morphology 
 

























Outcome of ATT 
(observation period) 
1 TTC F7 #5276 311 48 - yes - - 
2 TTC F10 #6653 166 48 - yes - - 
3 TTC F7 #6354 195 48 - yes - - 
4 TTC F10 #5785 294 19 - yes - - 
5 TTC F7 #3059 584 98 - yes - - 
6 TTC F10 #6587 177 37 - yes - - 
7 TTC F10 #5784 314 40 - yes - - 
8 TTC F7 #3055 410 203 - yes - - 
9 TTC F7 #7087 265 - - - 307 T cell signal 
10 TTC F7 #7091 265 - - - 307 T cell signal 
11 TTC F10 #6125 366 - 43 - 434 BL decrease but death 
12 TTC F7 #6585 289 - 78  - 400 Rejection (96 d) 
13 TTC F7 #6799 213 - 84  - 352 Rejection (154 d) 
14 TTC F10 #10172 262 - 113  - 430 Rejection (113 d) 
15 TTC F10 #10539 248 - 51  - 384 Rejection (180 d) 
16 TTC F10 #9978 342 - 65  - 456 Rejection (113 d) 
17 TTC F10 #9774 350 - 45 - 486 Rejection (56 d) 
18 TTC F7 #9387 422 - 99  - 548 Rejection (56 d) 
19 TTC F10 #P8157 223 - 64  - 434 Rejection (54 d) 
 
Tabelle 2: 
Mouse 1-8: group of mice was subjected to oncogene-inactivation therapy and received dox 
again after indicated time period. 
Mouse 9-10: group of mice was subjected to oncogene-inactivation therapy and received TE 
cells prior developing tumor relapse. RLuc T cell signal was followed. 
Mouse 11-19: group of mice was subjected to oncogene-inactivation therapy and received 
TE cell therapy after developing drug-resistant tumors. Mouse 15 and 17 were set on dox 
again starting four days prior T cell therapy. 
 
